Serogroups W and W-135
As per the AntigenCode subset recent update, the serogroup W135 is now an acceptable synonym for serogroup W. Please refer to the AntigenCode page for the details.
Current – Serogroup W-135:
Applying the change – Serogroup W:
Note that as per the editorial guidelines, when a FSN or PT changes, the initial description is kept for facilitating data searching and retrieving.
Known Issues
The vaccine products containing only Neisseria meningitidis serogroup A, C, W135 or W-135 and Y antigens (medicinal product) will require an update, as the Serogroup W and W-135 can now be considered equivalent.
Update to the varicella and herpes zoster vaccines
Varicella disorder and herpes zoster disorder are caused by the same organism: human alphaherpesvirus 3 (“varicella-zoster virus” is the historical name of this organism). The base antigen substance for both vaccine groups is the same: Antigen of human alphaherpesvirus 3.
As varicella and herpes zoster vaccines concepts cannot be differentiated by the active ingredient, the specific target disease must be stated in the FSN.
Define naming convention for the target disorder pattern in the FSN
<Vaccine for X disorder prevention> was applied in 2020 (CA vaccines remodeling project)
Examples:
FSN: Vaccine product containing only Human alphaherpesvirus 3 antigen for varicella prevention (medicinal product)|
FSN: Vaccine product containing only Human alphaherpesvirus 3 antigen for herpes zoster prevention (medicinal product)|
<Vaccine against X ORGANISM> was applied in 2021 (Int Edition) to resolve COVID-19 vaccine
Example:
FSN: Vaccine product against severe acute respiratory syndrome coronavirus 2 (medicinal product)|
Order of patterns:
Vaccine product containing <active ingredient pattern> <target disease pattern>
Examples:
FSN: Vaccine product containing Human alphaherpesvirus 3 antigen for herpes zoster prevention (medicinal product)
FSN: Vaccine product containing Human alphaherpesvirus 3 antigen against herpes zoster (medicinal product)
Define the level of granularity for the recombinant vaccine (new parent for Shingrix)
Pattern:
FSN: Vaccine product containing only Human alphaherpesvirus 3 recombinant surface glycoprotein E antigen for herpes zoster prevention (medicinal product)
This allows aligning with the already existing: Antigen of Human alphaherpesvirus 3 recombinant surface glycoprotein E (substance) concept.
Define CA PT for herpes zoster vaccines
For the existing concept with the Zos vaccine abbreviation, a change is proposed to specify this is a herpes zoster vaccine as follow:
FSN: Vaccine product containing only Human alphaherpesvirus 3 antigen for herpes zoster prevention (medicinal product)
New English PT: Zos hespes zoster unspecified
Additional English Syn: Zos zoster unspecified*
Additional English Syn: HZ herpes zoster unspecified **
* This description will be kept for historical and data search options.
** The HZ abbreviation has also been added for reference, since it is on the CIG page, although HZ is not listed in the VVWG.
A new vaccine has been created to distinguish the live attenuated herpes zoster vaccine
FSN: Vaccine product containing only live attenuated Human alphaherpesvirus 3 antigen for herpes zoster prevention (medicinal product)
English PT: LZV live attenuated herpes zoster unspecified
A new vaccine has been created to distinguish the recombinant herpes zoster vaccine
FSN: Vaccine product containing only Human alphaherpesvirus 3 recombinant surface glycoprotein E antigen for herpes zoster prevention (medicinal product)
English PT: RZV recombinant herpes zoster unspecified
The below sections are currently under review due to the Immunization RedesignIf you have questions or need information, please contact us |
---|
This content is designed for use when populating an immunization history when the client and/or the provider do not have the detail of the trade name of the vaccine administered OR the product has been discontinued and/or never licensed in Canada. Currently licensed products, described generically, are also included on this list as an immunization history may include products still available in Canada. It consists mainly of concepts from the Medicinal Entity class and from the SNOMED CT Pharmaceutical / biologic product hierarchy that are described using a “generic name”. With time, additional concepts represented by the trade name may be found in this subset when they are no longer licensed for use in Canada, but are required to capture historic data.
The scope of this subset is vaccines that are currently licensed for use in Canada (generic description, i.e. no trade name), those obtained through special access programs (generic description), and vaccines that have been discontinued and/or never licensed in Canada (with trade name). This content is intended to be used when populating an immunization history when the client and /or provider does not have the detail of the trade name (brand name) of the vaccine administered OR the product has been discontinued and/or never licensed in Canada. This subset will include concepts represented by a generic description for a vaccine that was previously administered to the client as may be expressed by the client or provider for an immunization history and concepts represented by the trade name for products that have been discontinued and/or never licensed in Canada.
When the subset is sorted to group the similar concepts together, the user can select a more detailed concept when available. For example it is possible to select an adult dose or a child dose, when that information is available. If there is not enough information to select such a detailed code, the user can then select a more generic code.
For example the Diphtheria group:
Concept Code | Concept Name | Preferred Synonym (English) | Preferred Synonym (French) |
428214002 | Diphtheria vaccine (product) | Diphtheria unspecified | Diphtérie non spécifié |
7701000087100 | Diphtheria standard dose vaccine (product) | D diphtheria pediatric unspecified | D diphtérie pédiatrique non spécifié |
7741000087102 | Diphtheria low dose vaccine (product) | d diphtheria adult unspecified | d diphtérie adulte non spécifié |
For example the Pertussis Group:
Concept Code | Concept Name | Preferred Synonym (English) | Preferred Synonym (French) |
61602008 | Pertussis vaccine (product) | Pertussis unspecified * | Coqueluche non spécifié * |
449019003 | Acellular pertussis vaccine (product) | Pertussis acellular unspecified * | Coqueluche acellulaire non spécifié * |
7771000087105 | Acellular pertussis standard dose vaccine (product) | aP pertussis acellular pediatric unspecified | Ca coqueluche acellulaire pédiatrique non spécifié |
7781000087107 | Acellular pertussis low dose vaccine (product) | ap pertussis acellular adult unspecified | ca coqueluche acellulaire adulte non spécifié |
7761000087101 | Whole cell pertussis standard dose vaccine (product) | wP pertussis whole cell pediatric unspecified | Coqueluche à germes entiers pédiatrique non spécifié |
*These descriptions do not have a current abbreviation assigned by PHAC (to avoid confusion with discontinued codes)
For example the HPV Group:
Concept Code | Concept Name | Preferred Synonym (English) | Preferred Synonym (French) |
424519000 | Human papillomavirus vaccine (product) | HPV human papillomavirus unspecified | VPH virus du papillome humain non spécifié |
7791000087109 | Human papillomavirus bivalent vaccine (product) | HPV-2 human papillomavirus bivalent unspecified | VPH-2 virus du papillome humain bivalent non spécifié |
7801000087108 | Human papillomavirus quadrivalent vaccine (product) | HPV-4 human papillomavirus quadrivalent unspecified | VPH-4 virus du papillome humain quadrivalent non spécifié |
20861000087100 | Human papillomavirus 9-valent vaccine (product) | HPV-9 human papillomavirus 9-valent unspecified | VPH-9 virus du papillome humain nonavalent non spécifié |
The Vaccine Historical Subset may list additional vaccine codes than those found in the CIG or the vaccine abbreviation list. This is to allow the data capture of generic products or trade name products that might not be available in Canada or are discontinued products of different formulation, strength and dosage.
For example:
Concept Code | Concept Name | Preferred Synonym (English) | Preferred Synonym (French) |
8211000087108 | Diphtheria standard dose + pertussis standard dose + tetanus + Haemophilus influenzae type b vaccine (product) | DPT-Hib diphtheria + pertussis + tetanus + Haemophilus influenzae type b pediatric unspecified | DCT-Hib diphtérie + coqueluche + tétanos + Haemophilus influenzae de type b pédiatrique non spécifié |
20601000087103 | Diptheria standard dose + pertussis standard dose + tetanus + hepatitis B vaccine (product) | DPT-HB diptheria + pertussis + tetanus + hepatitis B pediatric unspecified | DCT-HB diphtérie + coqueluche + tétanos + hépatite B pédiatrique non spécifié |
20591000087106 | Diptheria standard dose + pertussis standard dose + tetanus + hepatitis B + Haemophilus influenzae type b vaccine (product) | DPT-HB-Hib diptheria + pertussis + tetanus + hepatitis B + Haemophilus influenzae type b pediatric unspecified | DCT-HB-Hib diphtérie + coqueluche + tétanos + hépatite B + Haemophilus influenzae de type b pédiatrique non spécifié |
The format for the Fully Specified Name (FSN) is as follows:
A. For generic concepts
Vaccine Name (strength) vaccine (product)
E.g.: Diphtheria standard dose + tetanus vaccine (product)
For example: attenuated Bacillus Calmette Guerin (product) (This is an international concept)
For example: Hepatitis B virus vaccine regular strength (product) (This is a Canadian Edition concept)
For example: Acellular pertussis low dose vaccine (product) is for adults, and Acellular pertussis standard dose is for children
For example: Diphtheria standard dose + tetanus + acellular pertussis standard dose vaccine (product)
This is the semantic tag representing the context of use within SNOMED CT: for any concept that is within the Pharmaceutical / biologic product hierarchy.
B. For concepts that include a Trade Name
The format for the Preferred Synonym (PS) is as follows:
A. For generic concepts
PHAC Abbreviation Vaccine Name (qualifier) unspecified
Examples:
HA Hepatitis A unspecified
fIPV poliomyelitis inactivated fractional unspecified
this is an exeption introduced in the May 2024 release
IPV poliomyelitis inactivated standard dose unspecified
For example: Pertussis unspecified; was not allocated with the ‘P’ abbreviation because ‘P’ has been used as the abbreviation for Polio, and for Pertussis (discontinued for both)
For example: wP = pertussis whole cell
For example: d diphtheria adult unspecified and
D diphtheria pediatric unspecified
B. For concepts that include a Trade Name
Trade name products may be retired from the Canadian market due to decreased demand, replacement by another product, etc. When this happens, the trade name concept will be inactivated from the Administrable subset and activated in the historic subset.
Refer to the VaccineAdministeredTradeNameCode subset, Preferred Synonym section
For example: Inf Arepanrix GSK
Par exemple: HB Hepatitis B virus vaccine X strength (product)
Concept Code | Concept Name | Preferred Synonym (English) | Preferred Synonym (French) |
61602008 | Pertussis vaccine (product) | Pertussis unspecified * | Coqueluche non spécifié * |
449019003 | Acellular pertussis vaccine (product) | Pertussis acellular unspecified * | Coqueluche acellulaire non spécifié * |
7771000087105 | Acellular pertussis standard dose vaccine (product) | aP pertussis acellular pediatric unspecified | Ca coqueluche acellulaire pédiatrique non spécifié |
7781000087107 | Acellular pertussis low dose vaccine (product) | ap pertussis acellular adult unspecified | ca coqueluche acellulaire adulte non spécifié |
7761000087101 | Whole cell pertussis standard dose vaccine (product) | wP pertussis whole cell pediatric unspecified | Coqueluche à germes entiers pédiatrique non spécifié |